Latest: FDA Approves New Biosimilar for Oncology Treatment
Oncology

Atezolizumab Plus Chemo Safe, Efficacious in Broader ES-SCLC Population

by Cancer Network
0 Comments
0 Mins
The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.
Tags:
Cancer Network
Author

Cancer Network

Previous Post
Fertile ground
Next Post
Nonfocal Transient Neurologic Attacks Originate More From Socioeconomic Determinants Than Cardiovascular Risk Factors
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago